CROI 2013: Statins for People with HIV -- How Sweet Is It?
- Details
- Category: HIV-Related Conditions
- Published on Thursday, 21 March 2013 00:00
- Written by Matt Sharp
Statins may help reduce co-morbid conditions such as cardiovascular disease and lower mortality for some people with HIV, but with a possible trade-off of higher diabetes risk, according to a series of studies presented and discussed at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.
CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]
- Details
- Category: Search for a Cure
- Published on Wednesday, 20 March 2013 00:00
- Written by Gregory Fowler
The big news on the opening day of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) was a report about an infant with HIV who started combination antiretroviral treatment very early and now shows no evidence of replication-competent virus. "We equate this to our Berlin Patient," said Deborah Persaud from Johns Hopkins University School of Medicine. "It could get us on the road to a cure for HIV-infected children."
New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 March 2013 00:00
- Written by Anna Forbes
Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.
CROI 2013: HIV and Aging -- Are People with HIV at Greater Risk for Heart Disease and Cancer? [VIDEO]
- Details
- Category: HIV-Related Conditions
- Published on Wednesday, 20 March 2013 00:00
- Written by Gregory Fowler
Keri Althoff from the VA Medical Center and George Washington University Medical School described findings from a study looking at risk of non-AIDS conditions such as cardiovascular disease and cancer at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.
CROI 2013: Second-line NRTI-sparing HIV Regimen Proves Equally Effective
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra or Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and 2 or 3 nucleoside or nucleotide analogs in large study conducted in Australia, Africa, Latin America, and Asia, researchers from Sydney’s Kirby Institute reported this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort
- CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection
- CROI 2013: HIV+ Men at Increased Risk for Co-morbid Conditions Regardless of Age
- CROI 2013: Heart Disease Rises Only Slighter Faster with Age for People with HIV
Web Design and Development by